Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, December 13, 2010 DEPO, HMSY, SCSS, BMRN, GSS, SVNT Are Seasonally Ripe To Go Up In the Next Five Weeks
December 13, 2010 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of DEPOMED INC (NASDAQ:DEPO), HMS HOLDINGS CORP (NASDAQ:HMSY), SELECT COMFORT CORPORATION (NASDAQ:SCSS), BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), GOLDEN STAR RESOURCES LTD (AMEX:GSS), SAVIENT PHARMACEUTICALS INC (NASDAQ:SVNT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php
The following stocks are expected to go Up:
Symbol Company Expected Return Odds By The Following Date
DEPO DEPOMED INC 16.390 % 84.62% (11 of 13) Wednesday, January 12th 2011
HMSY HMS HOLDINGS CORP 16.260 % 94.12% (16 of 17) Thursday, January 20th 2011
SCSS SELECT COMFORT CORPORATION 16.150 % 100.00% (12 of 12) Tuesday, January 18th 2011
BMRN BIOMARIN PHARMACEUTICAL INC 15.780 % 100.00% (11 of 11) Thursday, January 13th 2011
GSS GOLDEN STAR RESOURCES LTD 15.390 % 76.47% (13 of 17) Friday, January 7th 2011
SVNT SAVIENT PHARMACEUTICALS INC 15.100 % 90.48% (19 of 21) Thursday, January 13th 2011
DEPOMED INC (NASDAQ:DEPO) - Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. It markets GLUMETZA for the treatment of type 2 diabetes in the United States and Canada; and Proquin XR for the treatment of uncomplicated urinary tract infection in the United States. The companys product candidates include DM-1796 for the treatment of postherpetic neuralgia, which has completed a Phase III clinical trial; Serada for the treatment of menopausal hot flashes, which has completed a Phase III clinical trial; DM-3458 for gastroesophageal reflux disease; and DM-1992 to treat Parkinson's disease, which has completed a Phase I clinical trial. It sells its products to wholesalers and retail pharmacies. The company has collaboration and license agreements with Solvay Pharmaceuticals, Inc.; PharmaNova, Inc.; Santarus, Inc.; Merck & Co., Inc.; Covidien, Ltd.; TEVA Pharmaceuticals USA, Inc.; King Pharmaceuticals, Inc.; Esprit Pharma, Inc.; LG Life Sciences, Ltd.; Rottapharm/Madaus S.r.l.; PharmaNova, Inc.; and Supernus Pharmaceuticals, Inc. Depomed, Inc. was founded in 1995 and is based in Menlo Park, California.
HMS HOLDINGS CORP (NASDAQ:HMSY) - HMS Holdings Corp. provides cost management services for government-sponsored health and human services programs. The company offers coordination of benefits, cost avoidance, and program integrity services, which enable customers to recover amounts due from third parties, avoid and reduce costs, and ensure regulatory compliance. Its coordination of benefits services route claims paid by a government program to the liable third party, which reimburses the government payor; cost avoidance services provide validated insurance coverage information that is used by government payors to reject claims that are the responsibility of a third party; and program integrity services are designed to review claims paid by government programs, identify payment errors, and recover the erroneous payments. The company also offers a suite of program integrity and payment accuracy solutions to detect fraud and improper payments. Its services include audit, compliance and education, data and analysis, eligibility verification, medical review, and investigation services. In addition, HMS Holdings provides independent external medical review on issues of quality of care, medical necessity, and experimental/investigational treatment services to state government and private clients; and audit programs, program design, benefit management, and general and pharmacy systems consulting services. It serves state Medicaid agencies, government-sponsored managed care plans, pharmacy benefit managers, child support agencies, the Veterans Health Administration (VHA), the Centers for Medicare & Medicaid Services (CMS), commercial plans, self-funded employer plans, and other healthcare payors. The company was founded in 1974 and is headquartered in New York, New York.
SELECT COMFORT CORPORATION (NASDAQ:SCSS) - Select Comfort Corp. develops, manufactures, markets, and supports adjustable-firmness beds and other sleep-related accessory products in the U.S. and Canada. It offers beds under the brand name Sleep Number. These provide fabrics and cover filling, additional cushion and padding, firmness control systems, and wireless remote controls. The company also offers accessory bedding products, including specialty pillows, mattress pads, bed foundations, and leg options; markets the Precision Comfort adjustable foundation, enabling consumers to raise the head or foot of the bed as well as to experience a massage using a handheld remote; and provides Sleep Number SofaBed products. Select Comfort also markets comforters and blankets under the brand Personal Warmth Collection and provides home delivery, assembly, and mattress removal services. As of Feb. 26, 2007, it owned and operated 440 retail stores. The company was founded in 1987 and is headquartered in Minneapolis.
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) - BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates. The companys approved products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used to treat genetic disease called mucopolysaccharidosis (MPS)VI; Kuvan tablet, a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); Aldurazyme, which is used to treat mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase; and Firdapse, an orphan drug for the treatment of lambert eaton myasthenic syndrome. Its other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is under Phase II clinical development for the treatment of PKU; GALNS (N-acetylgalactosamine 6-sulfatase), which is under in Phase I/II clinical development for the treatment of MPS IVA; and BMN 195, a Phase I clinical development product for the treatment of duchenne muscular dystrophy. The company is also conducting preclinical development of various other enzyme product candidates for genetic and other metabolic diseases, including BMN-185, an IgA protease for IgA nephropathy; and BMN-103, a glucosidase for pompe disease. In addition, BioMarin holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. The company sells its products to specialty pharmacies, hospitals acting as retailers, pharmaceutical wholesalers, and distributors in the United States, Europe, Latin America, and internationally. It has a strategic alliance with Merck Serono S.A. and collaboration with Genzyme Corporation. The company was founded in 1996 and is headquartered in Novato, California.
GOLDEN STAR RESOURCES LTD (AMEX:GSS) - Golden Star Resources Ltd., a gold mining and exploration company, through its subsidiaries, engages in the exploration and production of gold. Its principal properties include 90% interest in the Bogoso/Prestea mine having mining and exploration concessions covering a strike length of approximately 85 kilometers located along the Ashanti Trend in southwest Ghana; and 90% interest in the Wassa gold mine located in the southwestern region of Ghana. Golden Star also has an 81% interest in the Prestea Underground mine situated in Ghana, as well as gold exploration interests in other parts of West Africa and in the Guiana Shield of South America. The company was founded in 1984 and is based in Littleton, Colorado.
SAVIENT PHARMACEUTICALS INC (NASDAQ:SVNT) - Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. The KRYSTEXXA is being developed as a treatment for chronic gout in patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It sells its products directly to drug wholesalers. The company, formerly known as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in June 2003. Savient Pharmaceuticals, Inc. was founded in 1980 and is headquartered in East Brunswick, New Jersey.
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
About SQUEEZETRIGGER.COM
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
- WOPRAI
- support@woprai.com